当前位置:首页 - 行情中心 - 春立医疗(688236) - 财务分析 - 利润表

春立医疗

(688236)

  

流通市值:63.22亿  总市值:84.08亿
流通股本:2.88亿   总股本:3.84亿

利润表

报告期2025-03-312024-12-312024-09-302024-06-30
公司类型通用通用通用通用
一、营业总收入229,843,941.53805,857,022.19508,283,661.62380,130,570.92
  营业收入229,843,941.53805,857,022.19508,283,661.62380,130,570.92
二、营业总成本163,972,970.3678,243,060.18449,469,327.29304,028,844.65
  营业成本76,572,465.53268,952,851.12156,043,170.05108,247,815.46
  税金及附加1,960,604.517,723,578.586,012,961.594,342,874.75
  销售费用46,121,370.37240,247,102.81163,464,944.14111,481,168.8
  管理费用16,587,602.3545,290,473.7131,357,332.921,310,062.04
  研发费用26,897,460.32133,096,848.5999,676,406.767,659,413.06
  财务费用-4,166,532.78-17,067,794.63-7,085,488.09-9,012,489.46
  其中:利息费用-44,939.0727,847.2527,050.23
  其中:利息收入4,176,613.3716,309,711.038,960,596.258,040,034.97
三、其他经营收益
  加:公允价值变动收益1,604,306.849,434,830.146,079,575.334,670,205.47
  加:投资收益3,217,026.8610,980,482.179,122,896.796,084,909.58
  资产处置收益-15,716.8139,213.6139,213.6139,213.61
  资产减值损失(新)-790,286.65-33,776,793.41-9,409,707.93-5,229,285.17
  信用减值损失(新)-7,583,337.28-4,186,610.52-7,060,926.86-5,794,060.61
  其他收益2,183,975.4120,609,609.967,865,268.96,413,483.27
四、营业利润64,486,939.6130,714,693.9665,450,654.1782,286,192.42
  加:营业外收入0.04987,389.36870,286.2856,684.38
  减:营业外支出-102,914.25156,306.2172,914.25
五、利润总额64,486,939.64131,599,169.0766,164,634.1683,069,962.55
  减:所得税费用6,456,361.946,937,885.575,155,985.694,109,067.77
六、净利润58,030,577.7124,661,283.561,008,648.4778,960,894.78
(一)按经营持续性分类
  持续经营净利润58,030,577.7124,661,283.561,008,648.4778,960,894.78
(二)按所有权归属分类
  归属于母公司股东的净利润58,071,117.89124,988,009.5961,151,445.5579,026,078.82
  少数股东损益-40,540.19-326,726.09-142,797.08-65,184.04
  扣除非经常损益后的净利润52,698,123.3894,536,002.443,959,021.765,914,992.65
七、每股收益
  (一)基本每股收益0.150.330.160.21
  (二)稀释每股收益0.150.330.160.21
九、综合收益总额58,030,577.7124,661,283.561,008,648.4778,960,894.78
  归属于母公司股东的综合收益总额58,071,117.89124,988,009.5961,151,445.5579,026,078.82
  归属于少数股东的综合收益总额-40,540.19-326,726.09-142,797.08-65,184.04
公告日期2025-04-302025-03-292024-10-312024-08-31
审计意见(境内)标准无保留意见
TOP↑